Pharmacogenetic determinants of anti-cancer drug activity and toxicity

被引：44
作者：
Danesi, R
De Braud, F
Fogli, S
Di Paolo, A
Del Tacca, M
机构：
[1] Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Div Pharmacol & Chemotherapy, I-56126 Pisa, Italy
[2] European Inst Oncol, Div Med Oncol, Clin Pharmacol & New Drug Dev Unit, I-20142 Milan, Italy
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2001年 / 22卷 / 08期
关键词：
D O I：
10.1016/S0165-6147(00)01742-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cellular responses to anti-cancer agents result from the interaction between drugs, cellular targets and mechanisms of damage repair. Despite the pharmacological advances in the treatment of cancer, the clinical efficacy of chemotherapy is unpredictable in most patients. However, new information on the genetics of cancer delineates strategies by which the genetic background of tumour cells and patients might be profiled to select anti-cancer agents with improved efficacy and tolerability. This article focuses on the application of pharmacogenetics in the characterization of differences in the pharmacokinetics and pharmacodynamics of anti-cancer agents among individuals to define the likelihood of response and reduce the incidence of adverse effects.
引用
收藏
页码：420 / 426
页数：7
相关论文
共 54 条
[1]  
Ando Y, 2000, CANCER RES, V60, P6921
[2]   Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer [J].
Baekelandt, M ;
Holm, R ;
Nesland, JM ;
Tropé, CG ;
Kristensen, GB .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3775-3781
[3]   Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells [J].
Branch, P ;
Masson, M ;
Aquilina, G ;
Bignami, M ;
Karran, P .
ONCOGENE, 2000, 19 (28) :3138-3145
[4]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[5]  
Chen ZS, 1999, MOL PHARMACOL, V55, P921
[6]   Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents [J].
Ciardiello, F .
DRUGS, 2000, 60 (Suppl 1) :25-32
[7]  
Compagni A, 2000, BRIT J CANCER, V83, P1
[8]   Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer [J].
Cortazar, P ;
Johnson, BE .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1625-1631
[9]  
DEBRAUD F, 2001, P AM ASSOC CANC RES, V42, P1433
[10]   Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice [J].
Elstner, E ;
Müller, C ;
Koshizuka, K ;
Williamson, EA ;
Park, D ;
Asou, H ;
Shintaku, P ;
Said, JW ;
Heber, D ;
Koeffler, HP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8806-8811
123456